Erschienen in:
31.07.2020 | Letter to the Editor
Biosimilars for vasculitis: promise requires validation by quality studies
verfasst von:
Durga Prasanna Misra, Pallavi Patro, Vikas Agarwal
Erschienen in:
Clinical Rheumatology
|
Ausgabe 10/2020
Einloggen, um Zugang zu erhalten
Excerpt
We read with great interest the recent description of the effectiveness of rituximab biosimilar for induction and maintenance of remission in granulomatosis with polyangiitis (GPA) [
1]. The exploration of biosimilars in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [
2] and other vasculitides addresses an important knowledge gap, due to potential cost-savings and wider accessibility for biosimilars in low- and middle-income countries for the treatment of these chronic diseases. Real-world evidence often provides valuable information in this regard, complementary to higher quality evidence from randomized controlled trials [
3]. …